Skye Bioscience Receives Nasdaq Delisting Notice for Equity Shortfall
SKYE sits 25% above its 52-week low of $0.276 on elevated volume (4.3× avg).
Summary
Skye Bioscience received a Nasdaq delisting notice for failing to meet the $2.5 million minimum stockholders' equity requirement, with a compliance plan due by October 2, 2026.
Key Events · Legal and Risk Events · SKYE
-
Nasdaq Delisting Notice Received
On August 18, 2026, Skye received notice from Nasdaq that its stockholders' equity of ($497,307) falls below the $2,500,000 minimum required by Listing Rule 5550(b)(1).
-
Compliance Plan Deadline
Skye has 45 days, until October 2, 2026, to submit a plan to regain compliance. If accepted, Nasdaq may grant an extension up to February 14, 2027.
-
Listing Risk Amid Reverse Merger
The delisting notice arrives days after the announced reverse merger with Redx Pharma, which would leave Skye shareholders with only 5.38% of the combined company, and ahead of a 1-for-8 reverse split on August 24, 2026.
-
Company Evaluating Options
Skye states it is evaluating alternative courses of action to regain compliance, but there is no assurance it will succeed.
Analysis · SKYE · Life Sciences
Skye Bioscience received a Nasdaq delisting notice on August 18, 2026, because its stockholders' equity fell to negative $497,307, well below the $2.5 million minimum required for continued listing on the Nasdaq Capital Market. The company has 45 days to submit a compliance plan, with a possible extension to February 2027. This comes just days after the announcement of a reverse merger with Redx Pharma that would leave Skye shareholders with only 5.38% of the combined company, and a 1-for-8 reverse split is scheduled for August 24, 2026. The delisting notice adds immediate listing risk on top of the pending merger uncertainty.
How filings like this one have moved
In the 30 days to Oct 17, 2026, 44.5% of the 301 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.39%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SKYE was trading at $0.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $12.7M. The 52-week trading range was $0.28 to $4.99. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.